#Czech Republic #Prague #H2 Global Group #H2 Medical Technologies #H2 therapy

Czech Innovation in Alzheimer's Care

H2 Global Group, a pioneering entity in the MedTech sector, has recently marked a significant milestone in its journey towards innovation in Alzheimer's prevention and treatment. The company, along with its subsidiary H2 Medical Technologies, has officially entered a crucial stage of growth following their impressive showcase at LSI Europe 2025 in London. Here, they introduced a groundbreaking prototype medical device designed for controlled hydrogen therapy, specifically aimed at patients experiencing mild cognitive impairment—a common precursor to Alzheimer’s disease.

The Science Behind Hydrogen Therapy

The essence of this innovative device lies in its non-invasive technology, making it suitable for use both in clinical settings and at home. The device leverages a patented method that has been developed by a research team in Japan, led by Professor Shigeo Ohta, who is also a co-owner of H2 Global Group. Research has shown that molecular hydrogen possesses the unique capacity to protect brain cells from damage, reduce inflammation, and enhance neuronal metabolism and connectivity. As Professor Ohta articulates, "Hydrogen is the smallest molecule in the universe, yet it has the extraordinary potential to safeguard our most valuable assets—our memory and independence."

H2 Global Group's Strategic Roadmap

David Maršálek, the founder of H2 Global Group, has been at the forefront of hydrogen technology development since 2011. He emphasizes that the ambition of his team is to introduce the world's very first medical device centered on hydrogen for Alzheimer's prevention and therapeutic support. Backed by substantial scientific data, secured patent rights, and a proficient team, H2 Global Group is poised for success in a rapidly evolving market.

From 2021 to 2025, H2 Global Group successfully raised over $18 million in Seed funding. They have established a robust network comprising 20,000 end-customers and more than 50 business-to-business partners, leading to revenue growth that has surpassed $7.4 million. The latest valuation of the group stands at approximately $77 million, marking a significant achievement in its trajectory.

As the company transitions into Series A funding, it is aiming to raise between $25 million to $30 million to facilitate its global expansion into regions including Europe, the United States, the Middle East, and Africa. These funds will also be channeled towards completing clinical trials and obtaining registrations from EU and FDA authorities. With revenue projections estimating a rise to nearly $48 million by 2029, the future looks promising for H2 Global Group.

A Broader Portfolio of Solutions

H2 Medical Technologies' innovative approach does not stop at the hydrogen therapy device. The company also offers hydrogen generators and therapeutic systems designed for various applications, including spas, sports clubs, physiotherapy clinics, and even veterinary use. Additionally, H2 Pharm is developing a range of consumer hydrogen-based products, such as H2 Premium Water®, H2 Brain®, H2 Forte®, and H2 Dent Care®, which have all found commercial success through e-commerce and B2B channels.

"Such opportunities are truly rare," concludes Maršálek. "When future textbooks recount this era, our investors will proudly declare they were part of it. Hydrogen is not just an energy source; it is a life-giving molecule interlinking the world. Invest in Hydrogen!"

In summary, H2 Global Group’s commitment to innovating in the field of Alzheimer's care through hydrogen therapy represents not only a significant advancement in medical technology but also aligns with a broader vision to enhance the quality of life for those affected by neurodegenerative diseases.